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Background
Identification of immune biomarkers indicating potential
clinical benefit from immunotherapies may contribute to
the selection of the right patient for the right therapy.
We have recently reported that HLA-DRB1*11 and
HLA-A*24 alleles might serve as predictive factors for
immunological and clinical responses to vaccination
with AE37, the Ii-Key hybrid peptide of HER2776-790
(AE36) in prostate cancer patients. The purpose of this
study was to investigate the predictive significance of
DRB1*11 allele expression in relation to immunological
and clinical response in breast cancer patients vacci-
nated with AE37 in a randomized Phase II clinical trial.
Methods
This trial (ClinicalTrials.gov Identifier: NCT00524277)
enrolled node-positive or high risk node-negative
patients with any degree of HER2 expression (IHC 1-3+
or FISH > 1.2), rendered disease-free following standard
of care therapy. Patients were randomized to receive
either AE37+GM-CSF (vaccine group) or GM-CSF
alone (control group) in 6 monthly intradermal primary
inoculations followed by 4 boosters administered every
6 months. The current analysis includes data from 55
patients enrolled and vaccinated with AE37 in Greece,
where the frequency of HLA-DRB1*11 is high. HLA-typ-
ing and measurement of TGFb levels in serum were
performed using Luminex® technology. Immunologic
responses were assessed in vivo using the delayed-type
hypersensitivity (DTH) test and in vitro with IFN-g ELI-
SPOT assay.
Results
Of the 55 vaccinated pts, 31 were found to be DRB1*11+
(56%). At baseline prior to vaccination, 22% (12 out of
55) of the vaccinated patients demonstrated pre-existing
immunity against AE36 by IFN-g release (defined as
above the 75th percentile of all enrolled patients).
Among patients with pre-existing AE36 immunity, the
majority, 67% (8 out of 12), were found to be DRB1*11+.
Vaccine-induced DTH and IFNg responses, were aug-
mented in the vast majority of DRB1*11+ patients. No
correlation was observed between the pre-existing levels
of serum TGFb and the expression of the DRB1*11 allele.
With a median follow up of 71 months, Kaplan-Meir
analyses demonstrated a 22% and 72% relative reduction
in recurrence rate (RRR) in DRB1*11+ patients and those
with pre-existent immunity, respectively. Overall survival
analysis of DRB1*11+ patients showed a 50% relative
reduction in death rate (RRD), and a 74% RRD in patients
with pre-existent immunity.
Conclusions
Our data demonstrate both immunologic and clinical
advantage of vaccination therapy with AE37 among
patients expressing DRB1*11 and/or having pre-existing
HER2 immunity, highlighting their potential roles as
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